Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC4131183/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC4131183/. The analysis below is for the second page.

Title[redir]:
Getting TRAIL back on track for cancer therapy - PMC
Description:
Unlike other members of the TNF superfamily, the TNF-related apoptosis-inducing ligand (TRAIL, also known as Apo2L) possesses the unique capacity to induce apoptosis selectively in cancer cells in vitro and in vivo. This exciting discovery provided ...

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We're unsure how the site profits.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Ncbi.nlm.nih.gov might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

doi, google, scholar, pubmed, cancer, trail, apoptosis, cells, death, trailr, cell, caspase, activity, patients, receptor, pmc, article, clinical, free, tras, safe, phase, disc, combination, tumor, study, signaling, advanced, trailinduced, human, anticancer, cancers, responses, ligand, resistance, necrosis, clin, protein, expression, domain, biol, therapy, therapeutic, induction, receptors, shown, results, recombinant, agonistic, chemo,

Topics {✒️}

glycosyl-phosphatidyl-inositol-anchored receptor lacking glycosyl-phosphatidyl-inositol-anchored protein tnf-related apoptosis-inducing ligand leucine zipper isoleucine zipper tetrameric trail-r2-activating nanobody cancer-cell-selective trail-sensitizing agents [google scholar] paz-ares death-inducing signaling complex case-specific trail-sensitizing strategy endotoxin-induced serum factor potentially anti-apoptotic trail-rs mitochondrial outer membrane tumour necrosis factor death-inducing trail-rs death-inducing trail-rs cell-killing monoclonal antibody tumor necrosis factor death receptor-induced apoptosis death receptor—induced apoptosis tumor-suppressor protein p53 trail-r2-targeting agonistic antibodies trail-induced programmed necrosis proximity-induced conformational change pmc beta search tumor-cell-derived interleukin-4 tnfalpha-mediated cell death forming inactive hetero-complexes o-glycosylation enzyme galnt14 cd95-fc fusion protein trail-mediated dr5-disc formation proapoptotic ligand apo2l/trail k48-linked ubiquitin chains [google scholar] todaro [google scholar] saltz degli-esposti ma death-inducing receptor cancer-selective trail sensitizers trail-receptor-mediated apoptosis [google scholar] fulda [google scholar] yee impair trail-induced apoptosis countervail trail-induced apoptosis escape trail-induced apoptosis therapeutically target trail-rs kras wild-type cells high-dose trail treatments rocha-lima cm patient-derived cancer tissue apo2l/trail-dependent recruitment

Questions {❓}

  • How can reliable molecular markers be identified to select cancer patients that are likely to benefit from particular TRA-comprising therapies?
  • What are novel TRAs with improved pharmacokinetic properties which could be taken forward into clinical application without causing toxicity?
  • Which TRAIL-apoptosis sensitizing strategies should be considered for novel therapeutic combinations to overcome TRAIL resistance?
  • Why could the promising preclinical results obtained with TRAs not be successfully translated into anticancer activity in patients?

Social Networks {👍}(6)

External Links {🔗}(342)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • jQuery
  • jQuery module (jquery-3.6.0)
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {📦}

  • Ncbi

4.54s.